Ocular Therapeutix to Present Clinical Data at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting being held April 22-26, 2022 in Washington, D.C.

“We are excited to have such a large presence at this year’s ASCRS which we believe highlights the interest in DEXTENZA as well as our other ocular surface programs,” commented Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “The data we are presenting includes updates on DEXTENZA, which is commercially available to treat inflammation and pain associated ophthalmic surgery and ocular itching associated with allergic conjunctivitis, and OTX-DED for the treatment of dry eye disease. All of the data being presented continue to demonstrate the breadth of our proprietary hydrogel technology and its potential to meet unmet needs in many areas of the ophthalmic space.”

Ocular Therapeutix Presentations at ASCRS:

DEXTENZA (Post-operative Ocular Inflammation and Pain):

• Title: Real-World Safety Analysis of an Intracanalicular Dexamethasone Insert Using the Intelligent Research in Site (IRIS) Registry
  Session Title: Medications (Preoperative, Postoperative, Intraoperative)
  Session Date/Times: Sunday, April 24, 2022 at 1:30 PM-1:35 PM ET
  Location: WEWCC, Level 1, 143C
  Presenter: Robert T Chang, MD, ABO
• Title: Real-World Characteristics of Patients Treated with Intracanalicular Dexamethasone Insert: An IRIS Registry Analysis 2019-2021
  Session Title: Medications (Preoperative, Postoperative, Intraoperative)
  Session Date/Times: Sunday, April 24, 2022 at 1:43 PM-1:48 PM ET
  Location: WEWCC, Level 1, 143C
  Presenter: Michael Mbagwu, MD

DEXTENZA (Allergic Conjunctivitis):

• Title: Effects of Punctal Occlusion on Ocular Itching and Conjunctival Redness in Subjects with Allergic Conjunctivitis
  Session Title: Ocular Surface Disease
  Session Date/Times: Monday, April 25, 2022 at 8:28 AM-8:33 AM ET
  Location: WEWCC, Level 1, 143A
  Presenter: Steven M. Silverstein, MD, FACS, ABO
• Title: Sustained 30 Day Effect of an Intracanalicular Dexamethasone Insert for Treating Ocular Itching Associated with Allergic Conjunctivitis